Answers are grounded in this paper and cite their sources.
D1receptors located on striatonigral neurons and D2receptors located, together with A2Areceptors, on striatopallidal neurons are known to interact functionally. Usingin situhybridization, we examined the effects of D1and D2agonists and of an A2Aantagonist onc-fosmRNA in identified striatal neurons and in globus pallidus. The full D1agonist, SKF 82958 (1 mg/kg), induced a homogenous increase ofc-fosmRNA in the striatum. This increase occurred to a similar extent in D1and D2receptor-containing striatal neurons. Conversely, the D2agonist, quinelorane (2 mg/kg), decreasedc-fosmRNA in these populations but increased it in globus pallidus. The adenosine A2Areceptor antagonist, SCH 58261 (5 mg/kg), also decreasedc-fosmRNA in D2receptor-containing neurons in striatum but did not affect pallidalc-fosmRNA. Concomitant administration of either D1plus D2agonists or D1agonist plus A2Aantagonist caused a potentiation ofc-fosmRNA in striatal neurons expressing the D1receptor and in globus pallidus. However, only the combination of D1and D2agonists modified thec-fosmRNA expression to a “patchy” distribution. Our data show that (1)c-fosexpression can be activated through D1andinhibitedthrough A2Aor D2receptors in both striatal output pathways in normal rats, and (2) D2receptor stimulation as well as A2Areceptor blockade can interact with D1receptor activation to potentiatec-fosexpression in the striatum and the globus pallidus. The data also suggest that the topological alteration ofc-fosexpression after coadministration of D1and D2agonists involves D2receptors located on interneurons or presynaptically on dopaminergic nerve terminals.
No takes yet. Share an insight, caveat, or question.
Moine et al. (1997) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: